Study Details
Full Title
A Phase 4, Open-label, Multi-group Study of Rezdiffra® in
Combination with Concomitant Therapies Commonly Used
to Treat Comorbidities in Adults with MASH and Moderate-
to-Advanced (F2-F3) Fibrosis, Administered According to
their Approved Labeling
Combination with Concomitant Therapies Commonly Used
to Treat Comorbidities in Adults with MASH and Moderate-
to-Advanced (F2-F3) Fibrosis, Administered According to
their Approved Labeling
Principal Investigator
Mustafa
Bashir
Protocol Number
PRO00120641
Enrollment Status
Open to Enrollment